Switching between intravenous and oral pantoprazole

Journal of Clinical Gastroenterology

Volumn 32, Issue 1, 2001, Pages 27-32

  Pisegna, J R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acid aspiration; Gastroesophageal reflux; Pantoprazole; Peptic ulcer; Proton pump; Stress ulcer; Syndrome; Zollinger Ellison syndrome

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ANESTHESIA INDUCTION; ARTICLE; ASPIRATION PNEUMONIA; BIOEQUIVALENCE; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HOSPITAL PATIENT; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH ACID SECRETION; STRESS ULCER; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS; ENZYME INHIBITORS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; GUIDELINES; H(+)-K(+)-EXCHANGING ATPASE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; OMEPRAZOLE; SULFOXIDES;

EID: 0035167781     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200101000-00007     Document Type: Article

References (63)

1. Reflux oesophagitis and its treatment
2. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease
3. Why do apparently healthy people use antacid tablets?
4. Contemporary medical therapy for gastroesophageal reflux disease
5. Long-term management of gastroesophageal reflux disease and its complications
6. Gastroesophageal reflux disease. Pill, blade, or laparoscope?
7. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
8. Optimizing the pharmacology of acid control in acid-related disorders
9. Proton-pump inhibitors for gastric acid-related disease
10. Proton-pump inhibitors in acid-related diseases
11. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose-response study
12. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
13. Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders
14. Proton pump inhibitory therapy: Then and now
15. Therapeutic approaches to healing esophagitis
16. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis
17. Double-blind, placebo-controlled comparison of raheprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease
18. Pantoprazole heals erosive esophagitis (EE) more effectively and provides greater symptomatic relief than placebo or nizatidine in gastroesophageal reflux disease (GERD) patients
19. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial
20. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicentre study
21. A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial
22. Pantoprazole IV - Acid inhibitory treatment for upper GI-bleeding
23. 2-receptor antagonists
24. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome
25. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole
26. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease
27. Comparison of intravenous with oral pantoprazole in symptom relief and healing of reflux esophagitis
28. Zollinger-Ellison Syndrome (ZES) patients can replace oral proton pump inhibitors (PPIs) with intravenous (IV) pantoprazole (PANTO) without losing control of acid output (AO)
29. Beneficial effects of I.V. omeprazole (OME) in patients with peptic ulcer bleeding (PUB)
30. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: A prospective randomised controlled study
31. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding
32. Effect of I.V. omeprazole on the pH and volume of gastric contents before surgery
33. Intravenous administration of the proton pump inhibitor omeprazole reduces the risk of acid aspiration at emergency cesarean section
34. Symptomatic gastroesophageal reflux in acutely hospitalized patients
35. Asthma
36. Bronchodilators and other agents used in asthma
37. Pharmacotherapy for acid/peptic disorders
38. Effect of isopropamide on response to oral cimetidine in patients with Zollinger-Ellison syndrome
39. Lansoprazole and omeprazole in the treatment of acid peptic disorders
40. Zollinger-Ellison syndrome: Pathogenesis, diagnosis, and management
41. Drug absorption in gastrointestinal disease and surgery
42. Drugs used in gastrointestinal diseases
43. A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery
44. Stress ulcer prophylaxis in medical patients: Who, what, and how much?
45. A review of stress ulcer prophylaxis in the neurosurgical intensive care unit
46. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses
47. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients
48. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy
49. Intravenous administration of lansoprazole: A preliminary study of dose ranging and efficacy in upper gastrointestinal bleeding
50. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage
51. Optimization of acid suppression for patients with peptic ulcer bleeding: An intragastric pH-metry study with omeprazole
52. The potential clinical role of intravenous omeprazole
53. Correlation ambulatory 24 hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease
54. Recognizing atypical manifestations of GERD. Asthma, chest pain, and otolaryngologic disorders may be due to reflux
55. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain
56. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen
57. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease
58. +-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers
59. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery
60. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers
61. Lack of pantoprazole drug interactions in man: An updated review
62. Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress
63. Clinical efficacy and safety of an intravenous (IV) pantoprazole formulation in erosive reflux esophagitis